Press "Enter" to skip to content

New patent expiration for Gilead Sciences drug ATRIPLA

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug ATRIPLA

Annual Drug Patent Expirations for ATRIPLA
Annual Drug Patent Expirations for ATRIPLA

Atripla is a drug marketed by Gilead Sciences and is included in one NDA. It is available from five suppliers. There are sixteen patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for ATRIPLA.

This drug has one hundred and nine patent family members in thirty-one countries.

The generic ingredient in ATRIPLA is efavirenz; emtricitabine; tenofovir disoproxil fumarate. Five suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug ATRIPLA
Do NOT follow this link or you will be banned from the site!